论文部分内容阅读
Bladder cancer is the second most common genitourinary malignant disease in the USA, with an expected 69000 newly diagnosed cases each year, and 14 000 deaths.Today, neoplasm recurrence is a leading cause to failure in bladder cancer therapy and effective chemotherapeutic synergist is of urgent clinical need to enhance the chemotherapeutic drugs effects after TRC.Here, we developed an innovative approach that enhancing the chemotherapeutic effects via tumor cell-derived microparticles (T-MPs).